APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nano-antibody CDMO Services

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Nano-antibody CDMO Services Market Outlook and Growth Opportunities 2026

23 December 2025207 pages

Choose your research edition.

Industry ResearchNano-antibody CDMO Services Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Nano-antibody CDMO Services Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Nano-antibody CDMO Services Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nano-antibody CDMO Services Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Nano-antibody CDMO Services Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Nano-antibody CDMO Services market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Nano-antibody CDMO Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nano-antibody CDMO Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nano-antibody CDMO Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Nano-antibody CDMO Services market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Nano-antibody CDMO Services market include Nuoanjian Biotech, BioInno Biotechnology, Sanofi, Medicilon, Bioworkshops, Yaohai Bio, Abace Biotechnology, Shilpa Biologicals Private and ProBio, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Nano-antibody CDMO Services market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nano-antibody CDMO Services and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nano-antibody CDMO Services revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Nano-antibody CDMO Services market.

Nano-antibody CDMO Services Segment by Company

Nuoanjian Biotech

BioInno Biotechnology

Sanofi

Medicilon

Bioworkshops

Yaohai Bio

Abace Biotechnology

Shilpa Biologicals Private

ProBio

PolyPeptide

Pierre Fabre

PeptiFinder Biotech

Jotbody

ImmunoPrecise Antibodies

GenScript

Cultiply

CordenPharma

Bachem

Abzena

53Biologics

Nano-antibody CDMO Services Segment by Type

Vector Construction

Antigen Design

Gene Synthesis

Others

Nano-antibody CDMO Services Segment by Application

Pharmaceutical Companies

Biological Laboratories

Others

Nano-antibody CDMO Services Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Nano-antibody CDMO Services status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Nano-antibody CDMO Services key companies, revenue, market share, and recent developments.

3. To split the Nano-antibody CDMO Services breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Nano-antibody CDMO Services market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nano-antibody CDMO Services significant trends, drivers, influence factors in global and regions.

6. To analyze Nano-antibody CDMO Services competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nano-antibody CDMO Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nano-antibody CDMO Services and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nano-antibody CDMO Services.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nano-antibody CDMO Services industry.

Chapter 3: Detailed analysis of Nano-antibody CDMO Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Nano-antibody CDMO Services in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Nano-antibody CDMO Services in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nano-antibody CDMO Services Industry Trends Table 2. Nano-antibody CDMO Services Industry Drivers Table 3. Nano-antibody CDMO Services Industry Opportunities and Challenges Table 4. Nano-antibody CDMO Services Industry Restraints Table 5. Global Nano-antibody CDMO Services Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nano-antibody CDMO Services Revenue Share by Company (2021-2026) Table 7. Global Nano-antibody CDMO Services Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Nano-antibody CDMO Services Key Company Manufacturing Base & Headquarters Table 9. Global Nano-antibody CDMO Services Company, Product Type & Application Table 10. Global Nano-antibody CDMO Services Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Nano-antibody CDMO Services by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Vector Construction Table 15. Significant Companies of Antigen Design Table 16. Significant Companies of Gene Synthesis Table 17. Significant Companies of Others Table 18. Global Nano-antibody CDMO Services Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Nano-antibody CDMO Services Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Nano-antibody CDMO Services Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Nano-antibody CDMO Services Sales Value Share by Type (2021-2026) Table 22. Global Nano-antibody CDMO Services Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Pharmaceutical Companies Table 24. Significant Companies of Biological Laboratories Table 25. Significant Companies of Others Table 26. Global Nano-antibody CDMO Services Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Nano-antibody CDMO Services Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Nano-antibody CDMO Services Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Nano-antibody CDMO Services Sales Value Share by Application (2021-2026) Table 30. Global Nano-antibody CDMO Services Sales Value Share by Application (2027-2032) Table 31. Global Nano-antibody CDMO Services Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Nano-antibody CDMO Services Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Nano-antibody CDMO Services Sales Value Share by Region (2021-2026) Table 34. Global Nano-antibody CDMO Services Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Nano-antibody CDMO Services Sales Value Share by Region (2027-2032) Table 36. Global Nano-antibody CDMO Services Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Nano-antibody CDMO Services Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Nano-antibody CDMO Services Sales Value Market Share by Country (2021-2026) Table 39. Global Nano-antibody CDMO Services Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Nano-antibody CDMO Services Sales Value Market Share by Country (2027-2032) Table 41. Nuoanjian Biotech Company Information Table 42. Nuoanjian Biotech Business Overview Table 43. Nuoanjian Biotech Nano-antibody CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Nuoanjian Biotech Nano-antibody CDMO Services Product Portfolio Table 45. Nuoanjian Biotech Recent Development Table 46. BioInno Biotechnology Company Information Table 47. BioInno Biotechnology Business Overview Table 48. BioInno Biotechnology Nano-antibody CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. BioInno Biotechnology Nano-antibody CDMO Services Product Portfolio Table 50. BioInno Biotechnology Recent Development Table 51. Sanofi Company Information Table 52. Sanofi Business Overview Table 53. Sanofi Nano-antibody CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Sanofi Nano-antibody CDMO Services Product Portfolio Table 55. Sanofi Recent Development Table 56. Medicilon Company Information Table 57. Medicilon Business Overview Table 58. Medicilon Nano-antibody CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Medicilon Nano-antibody CDMO Services Product Portfolio Table 60. Medicilon Recent Development Table 61. Bioworkshops Company Information Table 62. Bioworkshops Business Overview Table 63. Bioworkshops Nano-antibody CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Bioworkshops Nano-antibody CDMO Services Product Portfolio Table 65. Bioworkshops Recent Development Table 66. Yaohai Bio Company Information Table 67. Yaohai Bio Business Overview Table 68. Yaohai Bio Nano-antibody CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Yaohai Bio Nano-antibody CDMO Services Product Portfolio Table 70. Yaohai Bio Recent Development Table 71. Abace Biotechnology Company Information Table 72. Abace Biotechnology Business Overview Table 73. Abace Biotechnology Nano-antibody CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Abace Biotechnology Nano-antibody CDMO Services Product Portfolio Table 75. Abace Biotechnology Recent Development Table 76. Shilpa Biologicals Private Company Information Table 77. Shilpa Biologicals Private Business Overview Table 78. Shilpa Biologicals Private Nano-antibody CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Shilpa Biologicals Private Nano-antibody CDMO Services Product Portfolio Table 80. Shilpa Biologicals Private Recent Development Table 81. ProBio Company Information Table 82. ProBio Business Overview Table 83. ProBio Nano-antibody CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. ProBio Nano-antibody CDMO Services Product Portfolio Table 85. ProBio Recent Development Table 86. PolyPeptide Company Information Table 87. PolyPeptide Business Overview Table 88. PolyPeptide Nano-antibody CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. PolyPeptide Nano-antibody CDMO Services Product Portfolio Table 90. PolyPeptide Recent Development Table 91. Pierre Fabre Company Information Table 92. Pierre Fabre Business Overview Table 93. Pierre Fabre Nano-antibody CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Pierre Fabre Nano-antibody CDMO Services Product Portfolio Table 95. Pierre Fabre Recent Development Table 96. PeptiFinder Biotech Company Information Table 97. PeptiFinder Biotech Business Overview Table 98. PeptiFinder Biotech Nano-antibody CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. PeptiFinder Biotech Nano-antibody CDMO Services Product Portfolio Table 100. PeptiFinder Biotech Recent Development Table 101. Jotbody Company Information Table 102. Jotbody Business Overview Table 103. Jotbody Nano-antibody CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Jotbody Nano-antibody CDMO Services Product Portfolio Table 105. Jotbody Recent Development Table 106. ImmunoPrecise Antibodies Company Information Table 107. ImmunoPrecise Antibodies Business Overview Table 108. ImmunoPrecise Antibodies Nano-antibody CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. ImmunoPrecise Antibodies Nano-antibody CDMO Services Product Portfolio Table 110. ImmunoPrecise Antibodies Recent Development Table 111. GenScript Company Information Table 112. GenScript Business Overview Table 113. GenScript Nano-antibody CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. GenScript Nano-antibody CDMO Services Product Portfolio Table 115. GenScript Recent Development Table 116. Cultiply Company Information Table 117. Cultiply Business Overview Table 118. Cultiply Nano-antibody CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Cultiply Nano-antibody CDMO Services Product Portfolio Table 120. Cultiply Recent Development Table 121. CordenPharma Company Information Table 122. CordenPharma Business Overview Table 123. CordenPharma Nano-antibody CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. CordenPharma Nano-antibody CDMO Services Product Portfolio Table 125. CordenPharma Recent Development Table 126. Bachem Company Information Table 127. Bachem Business Overview Table 128. Bachem Nano-antibody CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Bachem Nano-antibody CDMO Services Product Portfolio Table 130. Bachem Recent Development Table 131. Abzena Company Information Table 132. Abzena Business Overview Table 133. Abzena Nano-antibody CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. Abzena Nano-antibody CDMO Services Product Portfolio Table 135. Abzena Recent Development Table 136. 53Biologics Company Information Table 137. 53Biologics Business Overview Table 138. 53Biologics Nano-antibody CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. 53Biologics Nano-antibody CDMO Services Product Portfolio Table 140. 53Biologics Recent Development Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Nano-antibody CDMO Services Product Image Figure 2. Global Nano-antibody CDMO Services Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nano-antibody CDMO Services Market Size (2021-2032) & (US$ Million) Figure 4. Global Nano-antibody CDMO Services Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Vector Construction Image Figure 8. Antigen Design Image Figure 9. Gene Synthesis Image Figure 10. Others Image Figure 11. Global Nano-antibody CDMO Services Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Nano-antibody CDMO Services Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Nano-antibody CDMO Services Sales Value Share by Type (2021-2032) Figure 14. Pharmaceutical Companies Image Figure 15. Biological Laboratories Image Figure 16. Others Image Figure 17. Global Nano-antibody CDMO Services Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Nano-antibody CDMO Services Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Nano-antibody CDMO Services Sales Value Share by Application (2021-2032) Figure 20. Global Nano-antibody CDMO Services Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Nano-antibody CDMO Services Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Nano-antibody CDMO Services Sales Value (2021-2032) & (US$ Million) Figure 23. North America Nano-antibody CDMO Services Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Nano-antibody CDMO Services Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Nano-antibody CDMO Services Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Nano-antibody CDMO Services Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Nano-antibody CDMO Services Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Nano-antibody CDMO Services Sales Value (2021-2032) & (US$ Million) Figure 29. South America Nano-antibody CDMO Services Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Nano-antibody CDMO Services Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Nano-antibody CDMO Services Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Vector Construction
  • Antigen Design
  • Gene Synthesis
  • Others
Applications
  • Pharmaceutical Companies
  • Biological Laboratories
  • Others
Companies covered
  • Nuoanjian Biotech
  • BioInno Biotechnology
  • Sanofi
  • Medicilon
  • Bioworkshops
  • Yaohai Bio
  • Abace Biotechnology
  • Shilpa Biologicals Private
  • ProBio
  • PolyPeptide
  • Pierre Fabre
  • PeptiFinder Biotech
  • Jotbody
  • ImmunoPrecise Antibodies
  • GenScript
  • Cultiply
  • CordenPharma
  • Bachem
  • Abzena
  • 53Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Nano-antibody CDMO Services Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Nano-antibody CDMO Services Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Nano-antibody CDMO Services Market Dynamics
  1. 2.1 Nano-antibody CDMO Services Industry Trends
  2. 2.2 Nano-antibody CDMO Services Industry Drivers
  3. 2.3 Nano-antibody CDMO Services Industry Opportunities and Challenges
  4. 2.4 Nano-antibody CDMO Services Industry Restraints
3 Nano-antibody CDMO Services Market by Company
  1. 3.1 Global Nano-antibody CDMO Services Company Revenue Ranking in 2025
  2. 3.2 Global Nano-antibody CDMO Services Revenue by Company (2021-2026)
  3. 3.3 Global Nano-antibody CDMO Services Company Ranking (2024-2026)
  4. 3.4 Global Nano-antibody CDMO Services Company Manufacturing Base and Headquarters
  5. 3.5 Global Nano-antibody CDMO Services Company Product Type and Application
  6. 3.6 Global Nano-antibody CDMO Services Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Nano-antibody CDMO Services Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Nano-antibody CDMO Services Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Nano-antibody CDMO Services Market by Type
  1. 4.1 Nano-antibody CDMO Services Type Introduction
  2. 4.1.1 Vector Construction
  3. 4.1.2 Antigen Design
  4. 4.1.3 Gene Synthesis
  5. 4.1.4 Others
  6. 4.2 Global Nano-antibody CDMO Services Sales Value by Type
  7. 4.2.1 Global Nano-antibody CDMO Services Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Nano-antibody CDMO Services Sales Value by Type (2021-2032)
  9. 4.2.3 Global Nano-antibody CDMO Services Sales Value Share by Type (2021-2032)
5 Nano-antibody CDMO Services Market by Application
  1. 5.1 Nano-antibody CDMO Services Application Introduction
  2. 5.1.1 Pharmaceutical Companies
  3. 5.1.2 Biological Laboratories
  4. 5.1.3 Others
  5. 5.2 Global Nano-antibody CDMO Services Sales Value by Application
  6. 5.2.1 Global Nano-antibody CDMO Services Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Nano-antibody CDMO Services Sales Value by Application (2021-2032)
  8. 5.2.3 Global Nano-antibody CDMO Services Sales Value Share by Application (2021-2032)
6 Nano-antibody CDMO Services Regional Value Analysis
  1. 6.1 Global Nano-antibody CDMO Services Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nano-antibody CDMO Services Sales Value by Region (2021-2032)
  3. 6.2.1 Global Nano-antibody CDMO Services Sales Value by Region: 2021-2026
  4. 6.2.2 Global Nano-antibody CDMO Services Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Nano-antibody CDMO Services Sales Value (2021-2032)
  7. 6.3.2 North America Nano-antibody CDMO Services Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Nano-antibody CDMO Services Sales Value (2021-2032)
  10. 6.4.2 Europe Nano-antibody CDMO Services Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Nano-antibody CDMO Services Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Nano-antibody CDMO Services Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Nano-antibody CDMO Services Sales Value (2021-2032)
  16. 6.6.2 South America Nano-antibody CDMO Services Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Nano-antibody CDMO Services Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Nano-antibody CDMO Services Sales Value Share by Country, 2025 VS 2032
7 Nano-antibody CDMO Services Country-level Value Analysis
  1. 7.1 Global Nano-antibody CDMO Services Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nano-antibody CDMO Services Sales Value by Country (2021-2032)
  3. 7.2.1 Global Nano-antibody CDMO Services Sales Value by Country (2021-2026)
  4. 7.2.2 Global Nano-antibody CDMO Services Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Nano-antibody CDMO Services Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Nano-antibody CDMO Services Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Nano-antibody CDMO Services Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Nuoanjian Biotech
  2. 8.1.1 Nuoanjian Biotech Company Information
  3. 8.1.2 Nuoanjian Biotech Business Overview
  4. 8.1.3 Nuoanjian Biotech Nano-antibody CDMO Services Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Nuoanjian Biotech Nano-antibody CDMO Services Product Portfolio
  6. 8.1.5 Nuoanjian Biotech Recent Developments
  7. 8.2 BioInno Biotechnology
  8. 8.2.1 BioInno Biotechnology Company Information
  9. 8.2.2 BioInno Biotechnology Business Overview
  10. 8.2.3 BioInno Biotechnology Nano-antibody CDMO Services Revenue and Gross Margin (2021-2026)
  11. 8.2.4 BioInno Biotechnology Nano-antibody CDMO Services Product Portfolio
  12. 8.2.5 BioInno Biotechnology Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Nano-antibody CDMO Services Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Nano-antibody CDMO Services Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Medicilon
  20. 8.4.1 Medicilon Company Information
  21. 8.4.2 Medicilon Business Overview
  22. 8.4.3 Medicilon Nano-antibody CDMO Services Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Medicilon Nano-antibody CDMO Services Product Portfolio
  24. 8.4.5 Medicilon Recent Developments
  25. 8.5 Bioworkshops
  26. 8.5.1 Bioworkshops Company Information
  27. 8.5.2 Bioworkshops Business Overview
  28. 8.5.3 Bioworkshops Nano-antibody CDMO Services Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bioworkshops Nano-antibody CDMO Services Product Portfolio
  30. 8.5.5 Bioworkshops Recent Developments
  31. 8.6 Yaohai Bio
  32. 8.6.1 Yaohai Bio Company Information
  33. 8.6.2 Yaohai Bio Business Overview
  34. 8.6.3 Yaohai Bio Nano-antibody CDMO Services Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Yaohai Bio Nano-antibody CDMO Services Product Portfolio
  36. 8.6.5 Yaohai Bio Recent Developments
  37. 8.7 Abace Biotechnology
  38. 8.7.1 Abace Biotechnology Company Information
  39. 8.7.2 Abace Biotechnology Business Overview
  40. 8.7.3 Abace Biotechnology Nano-antibody CDMO Services Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Abace Biotechnology Nano-antibody CDMO Services Product Portfolio
  42. 8.7.5 Abace Biotechnology Recent Developments
  43. 8.8 Shilpa Biologicals Private
  44. 8.8.1 Shilpa Biologicals Private Company Information
  45. 8.8.2 Shilpa Biologicals Private Business Overview
  46. 8.8.3 Shilpa Biologicals Private Nano-antibody CDMO Services Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Shilpa Biologicals Private Nano-antibody CDMO Services Product Portfolio
  48. 8.8.5 Shilpa Biologicals Private Recent Developments
  49. 8.9 ProBio
  50. 8.9.1 ProBio Company Information
  51. 8.9.2 ProBio Business Overview
  52. 8.9.3 ProBio Nano-antibody CDMO Services Revenue and Gross Margin (2021-2026)
  53. 8.9.4 ProBio Nano-antibody CDMO Services Product Portfolio
  54. 8.9.5 ProBio Recent Developments
  55. 8.10 PolyPeptide
  56. 8.10.1 PolyPeptide Company Information
  57. 8.10.2 PolyPeptide Business Overview
  58. 8.10.3 PolyPeptide Nano-antibody CDMO Services Revenue and Gross Margin (2021-2026)
  59. 8.10.4 PolyPeptide Nano-antibody CDMO Services Product Portfolio
  60. 8.10.5 PolyPeptide Recent Developments
  61. 8.11 Pierre Fabre
  62. 8.11.1 Pierre Fabre Company Information
  63. 8.11.2 Pierre Fabre Business Overview
  64. 8.11.3 Pierre Fabre Nano-antibody CDMO Services Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Pierre Fabre Nano-antibody CDMO Services Product Portfolio
  66. 8.11.5 Pierre Fabre Recent Developments
  67. 8.12 PeptiFinder Biotech
  68. 8.12.1 PeptiFinder Biotech Company Information
  69. 8.12.2 PeptiFinder Biotech Business Overview
  70. 8.12.3 PeptiFinder Biotech Nano-antibody CDMO Services Revenue and Gross Margin (2021-2026)
  71. 8.12.4 PeptiFinder Biotech Nano-antibody CDMO Services Product Portfolio
  72. 8.12.5 PeptiFinder Biotech Recent Developments
  73. 8.13 Jotbody
  74. 8.13.1 Jotbody Company Information
  75. 8.13.2 Jotbody Business Overview
  76. 8.13.3 Jotbody Nano-antibody CDMO Services Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Jotbody Nano-antibody CDMO Services Product Portfolio
  78. 8.13.5 Jotbody Recent Developments
  79. 8.14 ImmunoPrecise Antibodies
  80. 8.14.1 ImmunoPrecise Antibodies Company Information
  81. 8.14.2 ImmunoPrecise Antibodies Business Overview
  82. 8.14.3 ImmunoPrecise Antibodies Nano-antibody CDMO Services Revenue and Gross Margin (2021-2026)
  83. 8.14.4 ImmunoPrecise Antibodies Nano-antibody CDMO Services Product Portfolio
  84. 8.14.5 ImmunoPrecise Antibodies Recent Developments
  85. 8.15 GenScript
  86. 8.15.1 GenScript Company Information
  87. 8.15.2 GenScript Business Overview
  88. 8.15.3 GenScript Nano-antibody CDMO Services Revenue and Gross Margin (2021-2026)
  89. 8.15.4 GenScript Nano-antibody CDMO Services Product Portfolio
  90. 8.15.5 GenScript Recent Developments
  91. 8.16 Cultiply
  92. 8.16.1 Cultiply Company Information
  93. 8.16.2 Cultiply Business Overview
  94. 8.16.3 Cultiply Nano-antibody CDMO Services Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Cultiply Nano-antibody CDMO Services Product Portfolio
  96. 8.16.5 Cultiply Recent Developments
  97. 8.17 CordenPharma
  98. 8.17.1 CordenPharma Company Information
  99. 8.17.2 CordenPharma Business Overview
  100. 8.17.3 CordenPharma Nano-antibody CDMO Services Revenue and Gross Margin (2021-2026)
  101. 8.17.4 CordenPharma Nano-antibody CDMO Services Product Portfolio
  102. 8.17.5 CordenPharma Recent Developments
  103. 8.18 Bachem
  104. 8.18.1 Bachem Company Information
  105. 8.18.2 Bachem Business Overview
  106. 8.18.3 Bachem Nano-antibody CDMO Services Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Bachem Nano-antibody CDMO Services Product Portfolio
  108. 8.18.5 Bachem Recent Developments
  109. 8.19 Abzena
  110. 8.19.1 Abzena Company Information
  111. 8.19.2 Abzena Business Overview
  112. 8.19.3 Abzena Nano-antibody CDMO Services Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Abzena Nano-antibody CDMO Services Product Portfolio
  114. 8.19.5 Abzena Recent Developments
  115. 8.20 53Biologics
  116. 8.20.1 53Biologics Company Information
  117. 8.20.2 53Biologics Business Overview
  118. 8.20.3 53Biologics Nano-antibody CDMO Services Revenue and Gross Margin (2021-2026)
  119. 8.20.4 53Biologics Nano-antibody CDMO Services Product Portfolio
  120. 8.20.5 53Biologics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst